First Long-Acting Olanzapine Without PDSS Risk: Teva's Phase 3 SOLARIS Trial Shows Breakthrough Safety

New Long-term Safety Data from the Completed Phase 3 SOLARIS Trial Support the Potential of Olanzapine LAI (TEV-‘749) as the First Long-Acting Olanzapine Treatment Option for Schizophrenia with No PDSS Observed

Through Week 56 in the SOLARIS trial, there were no suspected or confirmed post-injection delirium/sedation syndrome (PDSS) events observed with olanzapine LAI (TEV-'749) and its long-term systemic safety profile was consistent with other olanzapine formulations1Additional new data comparing initiation of…

New Long-term Safety Data from the Completed Phase 3 SOLARIS Trial Support the Potential of Olanzapine LAI (TEV-'749) as the First Long-Acting Olanzapine Treatment Option for Schizophrenia with No PDSS Observed

Through Week 56 in the SOLARIS trial, there were no suspected or confirmed post-injection delirium/sedation syndrome (PDSS) events observed with olanzapine...

First Long-Acting Olanzapine Without PDSS Risk: Teva's Phase 3 SOLARIS Trial Shows Breakthrough Safety

Long-term safety data shows no post-injection delirium syndrome in 3,470 injections of olanzapine LAI. Trial demonstrates consistent safety profile with 74% experiencing TEAEs through week 56.